Decision-Making For Patients With Resectable Breast Cancer: Individualized Decisions For and By Patients and Their Physicians

Authors: Charles L. Loprinzi MDa and Peter M. Ravdin MDa
View More View Less
  • a From Mayo Clinic, Rochester, Minnesota, and University of Texas Health Sciences Center, San Antonio, Texas.

Decisions regarding the use of adjuvant cytotoxic and hormonal therapies for women with breast cancer ideally should be made jointly by the patient and oncologist. For patients to be adequately involved in this decision-making process, they must be provided with appropriate education regarding the potential benefits and risks of adjuvant therapies. The recommended steps for doing this are: 1) understand baseline prognosis with locoregional therapy (surgery, radiation, or both) alone for the individual patient at hand; 2) determine the estimated benefit afforded by adjuvant therapy options for the individual patient; 3) estimate the risk of side effects of adjuvant therapy options; 4) convey the above information to the individual patient; 5) facilitate the individual patient's decision regarding adjuvant systemic therapy; and 6) support the patient's decision. Two computer-based tools (Numeracy and Adjuvant!) are available to facilitate this process.

Peter M. Ravdin has ownership interests and holds copyright for the program Adjuvant!; the program has been distributed without cost to health care professionals. Charles L. Loprinzi is employed by the Mayo Clinic, which maintains the web site for the patient access version of Numeracy. However, he has no financial interest in the program.

Correspondence: Charles L. Loprinzi, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 550905. E-mail: cloprinzi@mayo.edu
  • 1

    Levine MN, Gafni A, Markham B et al.. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med 1992;117:5358.

    • Search Google Scholar
    • Export Citation
  • 2

    Whelan T., Levine M, Gafni A et al.. Mastectomy or lumpectomy? Helping women make informed choices. J Clin Oncol 1999;17:17271735, 1999.

  • 3

    Whelan TJ, Levine MN, Gafni A et al.. Breast irradiation postlumpectomy: Development and evaluation of a decision instrument. J Clin Oncol 1995;13:847853.

    • Search Google Scholar
    • Export Citation
  • 4

    Cole BF, Gelber RD, Gelber S et al.. Polychemotherapy for early breast cancer: An overview of the randomized clinical trials with quality-adjusted survival analysis. Lancet 2001;358: 277286.

    • Search Google Scholar
    • Export Citation
  • 5

    Ravdin PM, Siminoff LA, Davis GJ et al.. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.

    • Search Google Scholar
    • Export Citation
  • 6

    Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972979.

  • 7

    Baum M, Ravdin PM. Decision-making in early breast cancer: Guidelines and decision tools. Eur J Cancer 2002;38:745749.

  • 8

    Adjuvant Therapy for Breast Cancer. NIH Consensus Statement Online 2000;17:1–23. http://consensus.nih.gov

  • 9

    Carlson RW, Anderson BO, Bensinger W et al.. National Comprehensive Cancer Network. NCCN Practice Guidelines for Breast Cancer. Oncology 2000;14:3349.

    • Search Google Scholar
    • Export Citation
  • 10

    Goldhirsch A, Glick JH, Gelber RD et al.. Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 2001;19:38173827.

    • Search Google Scholar
    • Export Citation
  • 11

    Schnitt SJ, Guidi AJ. Pathology and biological markers of invasive breast cancer. In: Harris JR, ed. Diseases of the Breast (2nd ed). Philadelphia: Lippincott Williams & Wilkins, 2000:449454.

    • Search Google Scholar
    • Export Citation
  • 12

    Loprinzi CL, Ravdin PM, de Laurentiis M et al.. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol 1994;12:14221426.

    • Search Google Scholar
    • Export Citation
  • 13

    National Cancer Institute. Surveillence, Epidemiology, and End Results. http://www-seer.ims.nci,nih.gov/

  • 14

    Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 2001;19: 18651878.

  • 15

    Anonymous. Polychemotherapy for early breast cancer: An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930942.

    • Search Google Scholar
    • Export Citation
  • 16

    Anonymous: Tamoxifen for early breast cancer: An overview of randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:14511467.

    • Search Google Scholar
    • Export Citation
  • 17

    Ravdin RM, Siminoff L, Hewlett J et al.. Evaluation of impact of communication tool generated by the computer program, Adjuvant!, on patients with early breast cancer and their doctors (Abstr. #119). Proc ASCO 2001;20:31a.

    • Search Google Scholar
    • Export Citation
  • 18

    Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998;16:515521.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 123 53 6
PDF Downloads 93 41 4
EPUB Downloads 0 0 0